ASX ANNOUNCEMENT **2 NOVEMBER 2023**

1st PATIENT DOSED IN PHASE 1B RECURRENT GLIOBLASTOMA CLINICAL TRIAL

- 1st patient dosed in the Phase 1B with CHM 1101 in brain cancer clinical trial
- The Phase 1B clinical trial builds off the recent positive Phase 1A clinical data
- Phase 1B clinical trial is in patients with recurrent/ progressive glioblastoma

Sydney, Australia, 2 November 2023: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to announce that the first patient in the Company's Phase 1B clinical trial in recurrent and/ or progressive glioblastoma multiforme (GBM) had received CHM 1101 CAR T cell treatment.

CHM 1101 is a first-in-class, autologous Chlorotoxin CAR T cell therapy currently being investigated in patients with recurrent and/ or progressive glioblastoma.

The first patient in the Phase 1B clinical trial was dosed at the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center in Austin, Texas. The patient received CHM 1101 therapy as second line therapy.

"We are very excited to have initiated the first patient at St David's Austin Medical Center," said Jason Litten, MD and Chief Medical Officer of Chimeric Therapeutics. "We are looking forward to building off our recently released positive Phase 1A clinical data and advancing the clinical development of this unique and potentially transformative cell therapy for patients with this devastating disease."

The Phase 1B clinical trial for CHM 1101, being conducted under a US IND, (ClinicalTrials.gov ID: NCT04214392) was designed as a two-part clinical trial (Part A, dose confirmation and Part B, dose expansion). The first patient was treated in Part A of the Phase 1B trial, the initial dose confirmation cohort of the trial.

Advancement to Part B of the trial was designed to be contingent upon the data from the Phase 1A clinical trial. These positive data were recently announced in heavily pretreated patients who received CHM 1101, on average, as 4th line therapy and demonstrated a 55% Disease Control Rate (DCR), ~10 months survival in patients who achieved disease control and with a manageable safety profile. One patient exceeded 18 months survival, two patients have exceeded 14 months survival and three patients remain alive and in follow up.

Based upon these positive data, upon completion of Part A of the trial, the study will advance to Part B of the trial, the dose expansion cohort. Upon successful completion of the Part B dose expansion cohort, the Company intends to design and initiate a registration trial, in collaboration with global regulatory feedback.

"We are thrilled to have reached this key milestone for Chimeric and the advancement of the CHM 1101 clinical development program," said Jennifer Chow, CEO and Managing Director of Chimeric Therapeutics. "We believe that the full potential of CHM 1101 for patients with recurrent and/ or progressive glioblastoma will only be unlocked through the advancement of our clinical development program and look forward to continuing to advance this trial forward."

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2023.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Initial positive data from the investigator-initiated phase 1A trial has been presented on patients treated in the first two dose levels of the trial.

CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating

safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in

combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au